News | November 30, 2022
Biocon Biologics completes acquisition of Viatris' Global Biosimilars Business
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
The progress has been encouraging with approvals and launches in the US, EU, Japan, Australia and Emerging Markets. Post Mylan Upjohn (Pfizer) merger, the scope has been extended to China as well.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The partnership is a significant step in delivering advanced cancer therapies to patients.
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
She was Group Chief Marketing Officer at CKA Birla Group in her last role
Subscribe To Our Newsletter & Stay Updated
